Literature DB >> 2234292

[Computed tomography in diagnosis of diffuse axonal injury].

Y Iwadate1, J Ono, Y Okimura, S Suda, K Isobe, A Yamaura.   

Abstract

Diffuse axonal injury (DAI) has been described in instances of prolonged traumatic coma on the basis of the neuropathological findings, but the same findings are also found in patients with cerebral concussion. Experimental studies confirm that the quality of survivors following trauma is directly proportional to the amount of primarily injured-axon. When the injured axon lies in a widespread area of the brain, outcome for the patient is always poor. In a series of 260 severely head-injured patients, based on their poor outcome, 69 (27%) were diagnosed as DAI. Because of their relatively good outcome, eighty-two patients (32%) were classified into non-DAI group. The predominant CT finding of DAI patients was intraparenchymal deep-seated hemorrhagic lesion. This was observed in 28 patients (41%). Normal CT was also observed in 11 patients (16%). On the other hand, 8 of the non-DAI group (10%) manifested deep-seated lesions. Diffuse cerebral swelling (DCS) appeared in both groups in the same incidence. Subarachnoid hematoma in the perimesencephalic cistern (SAH (PMC] and intraventricular hematoma (IVH) were observed in 64% of the DAI group, and in 23% of the non-DAI group. The available evidence indicates that various types of hematoma seen in the deep-seated structures of the brain do not have an absolute diagnostic value, but the frequency of hematoma is thought to increase in proportion to the amount of injured-axon.

Entities:  

Mesh:

Year:  1990        PMID: 2234292

Source DB:  PubMed          Journal:  No Shinkei Geka        ISSN: 0301-2603


  1 in total

1.  Diffuse Axonal Injury: Epidemiology, Outcome and Associated Risk Factors.

Authors:  Rita de Cássia Almeida Vieira; Wellingson Silva Paiva; Daniel Vieira de Oliveira; Manoel Jacobsen Teixeira; Almir Ferreira de Andrade; Regina Márcia Cardoso de Sousa
Journal:  Front Neurol       Date:  2016-10-20       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.